IMMUNOTOXIN THERAPY FOR PATIENTS WITH B CELL TUMORS

该计划项目的目的是启动使用蓖麻毒素A的临床试验 含链免疫毒素(A-IT)。将实施抗Delta-A-IT 静脉注射给患者sIgD B细胞淋巴瘤和白血病。在随后的 临床试验、溶酶促进剂和B链IT将用于 增强A-IT靶标细胞毒性。这些研究将需要 大量高纯度A、B的制备与表征 链，抗增量抗体，抗抗体和由此产生的ITS。vbl.使用 敏感的克隆性分析，将测试其杀灭sIgD的效力 体外肿瘤细胞及其对啮齿动物和小鼠的非特异性毒性 灵长类动物。初步试验的主要目标将是确定和 解决因使用这些智能交通系统而产生的问题。如果A-IT没有 如果出现副作用，则将进行后续的II期试验。

The aim of this program project is to initiate clinical trials using ricin A chain-containing immunotoxins (A-IT). Anti-delta-A-IT will be administered intravenously to patients sIgD B cell lymphomas and leukemias. In subsequent clinical trials, lysosomotropic agents and B-chain IT will be used to potentiate A-IT targent cell toxicity. These studies will necessitate the preparation and characterization of large amounts of highly purified A and B chain, anti-delta antibody, anti-antibody and the resulting ITs. Using sensitive clonal assays, the ITs will be tested for potency in killing sIgD tumor cells in vitro, as well as, their nonspecific toxicity in rodents and primates. The primary goal of the initial trial will be to determine and solve the problems resulting from the use of these ITs. If the A-IT does not induce side effects, then subsequent phase II trials will be performed.